{
  "id": 15685801,
  "title": "Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil",
  "url": "https://urgent.news/2026/10/20/samsung-bioepis-secures-10-year-exclusive-drug-supply-deal-in-brazil",
  "topic": "world",
  "section": "World",
  "published": "2026-10-20T02:22:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times-koreatimes",
    "url": "https://www.koreatimes.co.kr/business/companies/20261020/samsung-bioepis-secures-10-year-exclusive-drug-supply-deal-in-brazil"
  },
  "original_language": "en",
  "account": null,
  "summary": "Samsung Bioepis has secured a 10-year exclusive supply deal for SB12, a biosimilar of Soliris, in Brazil, marking a significant milestone for the Korean biopharmaceutical company in the Latin American market. The partnership agreement with the Brazilian Ministry of Health will provide a stable source of revenue for Samsung Bioepis, with the drug SB12 used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The agreement was facilitated through the government-led Productive Development Partnership program, further solidifying Samsung Bioepis' commitment to the Brazilian pharmaceutical market.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil",
        "url": "https://urgent.news/2026/10/20/samsung-bioepis-secures-10-year-exclusive-drug-supply-deal-in-brazil-15689043",
        "published": "2026-10-20T03:02:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}